CTLA4 and neoplasm: Combinations of RT with antibodies blocking inhibitory negative regulatory molecules on T cells, such as the monoclonal antibody ipilimumab against CTLA-4, are promising to induce systemic anti-tumor immune responses (Dewan et al., 2009).